the stem cell therapy market is estimated to be worth USD 8.5 Billion by 2030, claims Roots Analysis
Roots Analysis has done a detailedstudy on “Global Stem CellsMarket:Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic,Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal,Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow,Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, NeuralTissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent,Pluripotent))”covering key aspectsof the industry’s evolution and identifying potential future growthopportunities.
To order this 500+ page report, which features 185+ figuresand 220+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html
Key Market Insights
§ Eminent representatives from differentbiopharmaceutical companies confirm the growing interest in stem cell therapy research,highlighting the prevalent and anticipated trends in ongoing R&D activities.
§ Morethan 120 industry players are engaged in evaluating the potential of over 280stem cell therapy products for the treatment of a variety of diseaseindications.
§ Thepipeline features a variety of marketed / clinical therapies being evaluatedacross different stages targeting various types of stem cells; these productsare designed for administration via diverse routes of administration.
§ Stemcell therapies have demonstrated the applicability across over 25 uniquetherapeutic areas; cardiovascular, neurological, musculoskeletal and autoimmune/ inflammatory disorders are presently the primary focus.
§ Severalorganizations have extended financial support to aid research efforts in thisdomain; the current focus is on the evaluation of different stem cell typesacross multiple clinical conditions.
§ In thelast few years, over 540 clinical trials, evaluating various types of stem celltherapies in more than 52,000 patients, have been initiated; most of thesetrials are presently being conducted in centers across the US.
§ Asseveral therapy candidates progress towards regulatory approval, developers areexploring diverse commercialization strategies to be implemented across differentstages of a product’s launch cycle.
§ Owing tothe rising demand for stem cell therapies, and challenges associated withmanufacturing and scale up, industry players have demonstrated preferences toengage the services of contract service providers.
§ Morethan 80 industry / non-industry players, based in different regions across theglobe, claim to provide contract development and manufacturing services tocater to the specific unmet needs of therapy developers.
§ Futuregrowth of the market is likely to be driven by the success of different typesof stem cell therapies, which are allogeneic and autologous in nature, asstakeholders continue to remain optimistic about proprietary products.
§ Theforeseen future market opportunity, based on the revenue generation potentialof such therapies, is anticipated to be distributed across differenttherapeutic areas, end-users and key geographical regions.
§ Productsbased on bone marrow derived adult stem cells are likely to continue todominate the market in the mid-long term; adoption of therapies administeredvia novel routes of administration is likely to gradually rise.
For more information, please visit https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Stem Cell Therapies
3.2.1. Historical Evolution of Stem Cell Research
3.2.2. Classification of Stem Cells
3.2.2.1. Based on Source of Stem Cell
3.2.2.2. Based on Origin of Stem Cell
3.2.2.3. Based on Potency of Stem Cell
3.2.3. Administration of Stem Cell Therapies
3.2.4. Applications of Stem Cell Therapies
3.2.5. Challenges Associated with Development ofStem Cell Therapies
3.3. Regulatory Guidelines for Stem CellTherapies
3.3.1. Current Scenario
3.3.2. Regulatory Guidelines in North America
3.3.3. Regulatory Guidelines in Europe
3.3.4. Regulatory Guidelines in Japan
3.4. Prevalent Trends Related to Stem CellTherapies
3.4.1. Emerging Focus Areas
3.4.2. Key Historical Trends
3.4.3. Geographical Activity
3.5. Growth Drivers and Roadblocks
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Stem Cell Therapies: Marketed andDevelopment Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Source of Stem Cell
4.2.3. Analysis by Origin of Stem Cell
4.2.4. Analysis by Type of Stem Cell
4.2.5. Analysis by Lineage of Stem Cell
4.2.6. Analysis by Potency of Stem Cell
4.2.7. Analysis by Target Indication
4.2.8. Analysis by Therapeutic Area
4.2.9. Analysis by Route of Administration
4.3. Stem Cell Therapies: AdditionalInformation
4.3.1. Information on Dosage and Commercial Rights
4.3.2. Information on Designations Awarded
4.4. Stem Cell Therapies: List of TechnologyPlatforms
4.5. Stem Cell Therapies: List of TherapyDevelopers
4.5.1. Analysis by Year of Establishment
4.5.2. Analysis by Company Size
4.5.3. Analysis by Location of Headquarters
4.5.4. Analysis by Company Size and Location ofHeadquarters
4.5.5. Leading Drug Developers: Analysis by Numberof Stem Cell Therapies
4.5.6. Leading Drug Developers: 4D Bubble Analysisbased on Strength of Pipeline, Target Indication and Company Size
4.6. Heptagon Representation: Analysis by Phaseof Development and Key Therapeutic Area
4.7. Grid Representation: Analysis by Phase ofDevelopment, Source of Stem Cell and Therapeutic Area
4.8. Tree Map Representation: Analysis byTherapeutic Area and Size of the Company
4.9. World Map Representation: Analysis ofRegional Activity
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Anterogen
5.2.1. Company Overview
5.2.2. Product Portfolio: Clinical-Stage Stem CellTherapies
5.2.3. Recent Developments and Future Outlook
5.3. Athersys
5.3.1. Company Overview
5.3.2. Product Portfolio: Clinical-Stage Stem CellTherapies
5.3.3. Recent Developments and Future Outlook
5.4. CHA Biotech
5.4.1. Company Overview
5.4.2. Product Portfolio: Clinical-Stage Stem CellTherapies
5.4.3. Recent Developments and Future Outlook
5.5. Cytopeutics
5.5.1. Company Overview
5.5.2. Product Portfolio: Clinical-Stage Stem CellTherapies
5.5.3. Recent Developments and Future Outlook
5.6. Hope Biosciences
5.6.1. Company Overview
5.6.2. Product Portfolio: Clinical-Stage Stem CellTherapies
5.6.3. Recent Developments and Future Outlook
5.7. Mesoblast
5.7.1. Company Overview
5.7.2. Product Portfolio: Clinical-Stage Stem CellTherapies
5.7.3. Recent Developments and Future Outlook
5.8. Pluristem Therapeutics
5.8.1. Company Overview
5.8.2. Product Portfolio: Clinical-Stage Stem CellTherapies
5.8.3. Recent Developments and Future Outlook
5.9. Takeda Pharmaceutical
5.9.1. Company Overview
5.9.2. Product Portfolio: Clinical-Stage Stem CellTherapies
5.9.3. Recent Developments and Future Outlook
5.10. TICEBA
5.10.1. Company Overview
5.10.2. Product Portfolio: Clinical-Stage Stem CellTherapies
5.10.3. Recent Developments and Future Outlook
6. KEY THERAPEUTIC AREAS
6.1. Chapter Overview
6.2. Autoimmune / Inflammatory Disorders
6.2.1. Crohn’s Disease
6.2.1.1. Disease Description
6.2.1.2. Epidemiology
6.2.1.3. Current Treatment Options
6.2.1.4. Side Effects of Current Treatment Options
6.2.1.5. Stem Cell Therapies for Crohn’s Disease
6.2.2. Ulcerative Colitis
6.2.2.1. Disease Description
6.2.2.2. Epidemiology
6.2.2.3. Current Treatment Options
6.2.2.4. Side Effects of Current Treatment Options
6.2.2.5. Stem Cell Therapies for Ulcerative Colitis
6.3. Cardiovascular Disorders
6.3.1. Critical Limb Ischemia
6.3.1.1. Disease Description
6.3.1.2. Epidemiology
6.3.1.3. Current Treatment Options
6.3.1.3.1. PharmacologicalInterventions
6.3.1.3.2. EndovascularTreatments
6.3.1.3.3. SurgicalInterventions
6.3.1.4. Stem Cell Therapies for Critical Limb Ischemia
6.3.2. Heart Failure
6.3.2.1. Disease Description
6.3.2.2. Epidemiology
6.3.2.3. Current Treatment Options
6.3.2.3.1. PharmacologicalInterventions
6.3.2.3.2. TherapeuticDevices
6.3.2.3.3. SurgicalInterventions
6.3.2.4. Stem Cell Therapies for Heart Failure
6.3.3. Myocardial Infarction
6.3.3.1. Disease Description
6.3.3.2. Epidemiology
6.3.3.3. Current Treatment Options
6.3.3.3.1. PharmacologicalInterventions
6.3.3.3.2. SurgicalInterventions
6.3.3.4. Stem Cell Therapies for Myocardial Infarction
6.4. Dermatological Disorders
6.4.1. Acne Vulgaris
6.4.1.1. Disease Description
6.4.1.2. Epidemiology
6.4.1.3. Current Treatment Options
6.4.1.4. Side Effects of Current Treatment Options
6.4.1.5. Stem Cell Therapies for Acne Vulgaris
6.5. Metabolic Disorders
6.5.1. Diabetes
6.5.1.1. Disease Description
6.5.1.2. Associated Health Risks / Complications
6.5.1.3. Epidemiology
6.5.1.4. Disease Diagnosis
6.5.1.5. Current Treatment Options
6.5.1.5.1. InsulinTherapies
6.5.1.5.2. Non-InsulinTherapies
6.5.1.6. Side Effects of Current Treatment Options
6.5.1.7. Stem Cell Therapies for Diabetes
6.5.2. Non-alcoholic Steatohepatitis (NASH)
6.5.2.1. Disease Description
6.5.2.2. Epidemiology
6.5.2.3. Current Treatment Options
6.5.2.4. Stem Cell Therapies for NASH
6.6. Oncological Disorders
6.6.1. Bladder Cancer
6.6.1.1. Disease Description
6.6.1.2. Epidemiology
6.6.1.3. Current Treatment Options
6.6.1.4. Stem Cell Therapies for Bladder Cancer
6.6.2. Breast Cancer
6.6.2.1. Disease Description
6.6.2.2. Epidemiology
6.6.2.3. Current Treatment Options
6.6.2.4. Stem Cell Therapies for Breast Cancer
6.6.3. Colorectal Cancer
6.6.3.1. Disease Description
6.6.3.2. Epidemiology
6.6.3.3. Current Treatment Options
6.6.3.4. Side Effects of Current Treatment Options
6.6.3.5. Stem Cell Therapies for Colorectal Cancer
6.6.4. Kidney Cancer
6.6.4.1. Disease Description
6.6.4.2. Epidemiology
6.6.4.3. Current Treatment Options
6.6.4.4. Stem Cell Therapies for Kidney Cancer
6.6.5. Liver Cancer
6.6.5.1. Introduction
6.6.5.2. Epidemiology
6.6.5.3. Current Treatment Options
6.6.5.4. Stem Cell Therapies for Liver Cancer
6.6.6. Lung Cancer
6.6.6.1. Disease Description
6.6.6.2. Epidemiology
6.6.6.3. Current Treatment Options
6.6.6.4. Side Effects of Current Treatment Options
6.6.6.5. Stem Cell Therapies for Lung Cancer
6.6.7. Ovarian Cancer
6.6.7.1. Disease Description
6.6.7.2. Epidemiology
6.6.7.3. Current Treatment Options
6.6.7.4. Stem Cell Therapies for Ovarian Cancer
6.6.8. Pancreatic Cancer
6.6.8.1. Disease Description
6.6.8.2. Epidemiology
6.6.8.3. Current Treatment Options
6.6.8.4. Stem Cell Based Therapies for Pancreatic Cancer
6.7. Neurological Disorders
6.7.1. Alzheimer’s Disease
6.7.1.1. Disease Description
6.7.1.2. Epidemiology
6.7.1.3. Symptoms of the Disease
6.7.1.4. Causes of Alzheimer’s Disease
6.7.1.5. Stages of Alzheimer’s Disease
6.7.1.6. Current Treatment Options
6.7.1.7. Stem Cell Therapies for Alzheimer’s Disease
6.7.2. Parkinson’s Disease
6.7.2.1. Disease Description
6.7.2.2. Epidemiology
6.7.2.3. Current Treatment Options
6.7.2.3.1. PharmacologicalManagement of Parkinson’s Disease
6.7.2.3.2. Non-PharmacologicalManagement of Parkinson’s Disease
6.7.2.3.3. Managementof Parkinson’s Disease Using Dietary Supplements
6.7.2.4. Stem Cell Therapies for Parkinson’s Disease
7. ASSESSMENT OF RELATIVE COMPETITION ANDGROWTH OPPORTUNITIES
7.1. Chapter Overview
7.2. Assumptions and Methodology
7.3. Analysis of Relative Competition andGrowth Opportunities
7.3.1. Established Therapeutic Areas in EmergingRegions
7.3.2. Established Therapeutic Areas in EstablishedRegions
7.3.3. Emerging Therapeutic Areas in EmergingRegions
7.3.4. Emerging Therapeutic Areas in EstablishedRegions
8. ACADEMIC GRANTS ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Stem Cell Therapies: Analysis of GrantsAwarded by the National Institutes of Health (NIH)
8.3.1. Analysis by Year of Award
8.3.2. Analysis by Amount Awarded
8.3.3. Analysis by Administering Institute Center
8.3.4. Analysis by Funding Institute Center
8.3.5. Analysis by Support Period
8.3.6. Analysis by Funding Institute Center andSupport Period
8.3.7. Most Popular NIH Spending Categorizations
8.3.8. Analysis by Funding Mechanism
8.3.9. Emerging Focus Areas
8.3.10. Analysis by Source of Stem Cell
8.3.11. Analysis by Origin of Stem Cell
8.3.12. Analysis by Type of Stem Cell
8.3.13. Analysis by Lineage of Stem Cell
8.3.14. Analysis by Potency of Stem Cell
8.3.15. Analysis by Therapeutic Area
8.3.16. Analysis by Type of Grant Application
8.3.17. Popular NIH Departments
8.3.18. Analysis by Study Section
8.3.19. Analysis by Types of Recipient Organizations
8.3.20. Popular Recipient Organizations
8.3.21. Analysis by Grant Mechanism
8.3.22. Prominent Program Officers
8.3.23. Regional Distribution of RecipientOrganizations
8.4. Grant Attractiveness Analysis
9. CLINICAL TRIAL ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Stem Cell Therapies: Clinical TrialAnalysis
9.3.1. Analysis by Trial Registration Year
9.3.2. Analysis by Trial Phase
9.3.3. Analysis by Number of Patients Enrolled byTrial Registration Year
9.3.4. Analysis by Study Design
9.3.5. Analysis by Trial Recruitment Status
9.3.6. Analysis by Sponsor / Collaborator
9.3.7. Leading Industry Sponsors: Based on Number ofRegistered Trials
9.3.8. Analysis by Trial Focus
9.3.9. Analysis by Type of Stem Cell
9.3.10. Analysis by Therapeutic Area
9.3.11. Analysis by Type of Stem Cell and TherapeuticArea
9.3.12. Geographical Analysis by Number of Clinical Trials
9.3.13. Geographical Analysis by Trial RecruitmentStatus
9.3.14. Geographical Analysis by Enrolled PatientPopulation
10. STEM CELL MANUFACTURING MARKET LANDSCAPEAND KPIs FOR EVALUATING CONTRACTSERVICES PARTNERS
10.1. Chapter Overview
10.2. Stem Cell Therapy Manufacturing
10.2.1. Need for Stem Cell Therapy ContractManufacturing
10.2.2. Advantages of Outsourcing Stem Cell TherapyManufacturing
10.2.3. Guidelines for Selecting a ContractManufacturing Organization (CMO) Partner
10.2.4. Stem Cell Therapy CMOs: List of IndustryPlayers
10.2.4.1. Analysis byYear of Establishment
10.2.4.2. Analysis byCompany Size
10.2.4.3. Analysis byScale of Stem Cell Manufacturing
10.2.4.4. Analysis byLocation of Headquarters
10.2.4.5. Analysis byLocation of Manufacturing Facilities
10.2.4.6. Analysis byTypes of Services Offered
10.2.4.7. Analysis bySource and Origin of Stem Cell
10.2.5. Stem Cell Therapy CMOs: List of Non-IndustryPlayers
10.2.5.1. Analysis byYear of Establishment
10.2.5.2. Analysis byScale of Stem Cell Manufacturing
10.2.5.3. Analysis byLocation of Headquarters
10.2.5.4. Analysis byLocation of Manufacturing Facilities
10.2.5.5. Analysis byTypes of Services Offered
10.2.5.6. Analysis bySource and Origin Stem Cell
10.3. Stem Cell Therapy Manufacturing: KPIAnalysis
10.3.1. KPI Definitions
10.3.1.1. FinancialIndicators
10.3.1.1.1. BigPharma Perspective
10.3.1.1.2. ContractManufacturers’ Perspective
10.3.1.2. Process andCapability Indicators
10.3.1.2.1. BigPharma Perspective
10.3.1.2.2. ContractManufacturers’ Perspective
10.3.1.3. MarketReputation Indicators
10.3.1.3.1. BigPharma Perspective
10.3.1.3.2. ContractManufacturers’ Perspective
10.4. Concluding Remarks
11. STEM CELL THERAPY DEVELOPERS AND CMOs: OPPORTUNITYASSESSMENT
11.1. Chapter Overview
11.2. Therapy Developers and CMOs in NorthAmerica
11.2.1. Gap Analysis by Scale of Stem CellManufacturing
11.2.2. Gap Analysis by Source of Stem Cell
11.2.3. Gap Analysis by Origin of Stem Cell
11.3. Therapy Developers and CMOs in Europe
11.3.1. Gap Analysis by Scale of Stem CellManufacturing
11.3.2. Gap Analysis by Source of Stem Cell
11.3.3. Gap Analysis by Origin of Stem Cell
11.4. Therapy Developers and CMOs in Asia-Pacificand Rest of the World
11.4.1. Gap Analysis by Scale of Stem CellManufacturing
11.4.2. Gap Analysis by Source of Stem Cell
11.4.3. Gap Analysis by Origin of Stem Cell
11.5. Concluding Remarks
12. KEY COMMERCIALIZATION STRATEGIES
12.1. Chapter Overview
12.2. Successful Drug Launch Strategy: ROOTSFramework
12.3. Successful Drug Launch Strategy: ProductDifferentiation
12.4. Commonly Adopted CommercializationStrategies based on Stage of Product Development
12.5. Key Approved Stem Cell Therapies: Profiles
12.5.1. CARTISTEM®
12.5.2. HiQCell®
12.5.3. Prochymal®
12.5.4. Strimvelis®
12.6. Key Commercialization Strategies Adopted byStem Cell Therapy Developers
12.6.1. Strategies Adopted before Therapy Approval
12.6.1.1. Participationin Global Events
12.6.1.2. Collaborationwith Stakeholders and Pharmaceutical Firms
12.6.1.3. SeekingApproval for Multiple Target Indications
12.6.1.4. SeekingSpecial Therapy Designations and Other Credentials
12.6.1.5. LeveragingUniqueness to Establish Competitive Edge
12.6.1.6. Anticipationof Likely Market Dynamics and Trends
12.6.1.7. OutsourcingManufacturing Operations
12.6.2. Strategies Adopted Post Therapy Approval
12.6.2.1. GeographicalExpansion
12.6.2.2. Participationin Global Events
12.6.2.3. PatientAssistance Programs
12.6.2.4. MiscellaneousPrograms
12.7. Opportunities and Challenges withUnapproved Therapies
12.8. Concluding Remarks
13. MARKET FORECAST
13.1. Chapter Overview
13.2. Scope and Limitations
13.3. Forecast Methodology and Key Assumptions
13.4. Overall Stem Cell Therapies Market,2020-2030
13.4.1. Stem Cell Therapies Market: Distribution bySource of Stem Cell
13.4.1.1. Stem CellTherapies Market for Allogeneic Therapies, 2020-2030
13.4.1.2. Stem CellTherapies Market for Autologous Therapies, 2020-2030
13.4.2. Stem Cell Therapies Market: Distribution byOrigin of Stem Cell
13.4.2.1. Stem CellTherapies Market for Adult Stem Cells, 2020-2030
13.4.2.2. Stem CellTherapies Market for Embryonic Stem Cells, 2020-2030
13.4.3. Stem Cell Therapies Market: Distribution byType of Stem Cell
13.4.3.1. Stem CellTherapies Market for Hematopoietic Stem Cells, 2020-2030
13.4.3.2. Stem CellTherapies Market for Mesenchymal Stem Cells, 2020-2030
13.4.3.3. Stem CellTherapies Market for Progenitor Cells, 2020-2030
13.4.3.4. Stem CellTherapies Market for Others, 2020-2030
13.4.4. Stem Cell Therapies Market: Distribution byLineage of Stem Cell
13.4.4.1. Stem CellTherapies Market for Adipose Tissue Derived Stem Cells, 2020-2030
13.4.4.2. Stem Cell TherapiesMarket for Bone Marrow Derived Stem Cells, 2020-2030
13.4.4.3. Stem CellTherapies Market for Cord Blood Derived Stem Cells, 2020-2030
13.4.4.4. Stem CellTherapies Market for Others, 2020-2030
13.4.5. Stem Cell Therapies Market: Distribution by Routeof Administration
13.4.5.1. Stem CellTherapies Market for Intraarticular Therapies, 2020-2030
13.4.5.2. Stem CellTherapies Market for Intracoronary Therapies, 2020-2030
13.4.5.3. Stem CellTherapies Market for Intramuscular Therapies, 2020-2030
13.4.5.4. Stem CellTherapies Market for Intramyocardial Therapies, 2020-2030
13.4.5.5. Stem CellTherapies Market for Intrathecal Therapies, 2020-2030
13.4.5.6. Stem CellTherapies Market for Intravenous Therapies, 2020-2030
13.4.5.7. Stem CellTherapies Market for Surgical Implants, 2020-2030
13.4.5.7. Stem CellTherapies Market for Others, 2020-2030
13.4.6. Stem Cell Therapies Market: Distribution byTherapeutic Area
13.4.6.1. Stem CellTherapies Market for Autoimmune / Inflammatory Disorders, 2020-2030
13.4.6.2. Stem CellTherapies Market for Cardiovascular Disorders, 2020-2030
13.4.6.3. Stem CellTherapies Market for Metabolic Disorders, 2020-2030
13.4.6.4. Stem CellTherapies Market for Musculoskeletal Disorders, 2020-2030
13.4.6.5. Stem CellTherapies Market for Neurological Disorders, 2020-2030
13.4.6.6. Stem CellTherapies Market for Oncological Disorders, 2020-2030
13.4.6.7. Stem CellTherapies Market for Ophthalmic Disorders, 2020-2030
13.4.6.8. Stem CellTherapies Market for Others, 2020-2030
13.4.7. Stem Cell Therapies Market: Distribution byEnd-Users
13.4.7.1. Stem CellTherapies Market for Ambulatory Surgery Centers, 2020-2030
13.4.7.2. Stem CellTherapies Market for Hospitals, 2020-2030
13.4.7.3. Stem CellTherapies Market for Specialty Clinics, 2020-2030
13.4.8. Stem Cell Therapies Market: Distribution byKey Geographical Regions
13.4.8.1. Stem CellTherapies Market in North America, 2020-2030
13.4.8.2. Stem CellTherapies Market in Europe, 2020-2030
13.4.8.3. Stem CellTherapies Market in Asia-Pacific and Rest of the World, 2020-2030
13.5. Concluding Remarks
14. CONCLUSION
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Seraxis
15.2.1. Company Snapshot
15.2.2. Interview Transcript: William L Rust, Founderand Chief Executive Officer
15.3. Xcelthera
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Xuejun Huang Parsons,Chief Executive Officer
15.4. Kadimastem
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Michel Revel, Co-Founder/ Chief Scientist and Galit Mazooz-Perlmuter, Director,Business Development
15.5. Heartseed
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Kikuo Yasui, Directorand Chief Operating Officer
15.6. University of Rostock
15.6.1. Organization Snapshot
15.6.2. Interview Transcript: Gustav Steinhoff,Director and Chairman, Department of Cardiac Surgery
15.7. Bio Elpida
15.7.1. Company Snapshot
15.7.2. Interview Transcript: Gilles Devillers,President
15.8. Roslin Cell Therapies
15.8.1. Company Snapshot
15.8.2. Interview Transcript: Fiona Bellot, BusinessDevelopment Manager
15.9. University of Minnesota
15.9.1. Organization Snapshot
15.9.2. Interview Transcript: David Mckenna, Professorand American Red Cross Chair in Transfusion Medicine
15.10. Waisman Biomanufacturing
15.10.1.CompanySnapshot
15.10.2.InterviewTranscript: Brian Dattilo, Manager of Business Development
15.11. YposKesi
15.11.1.CompanySnapshot
15.11.2.InterviewTranscript: Mathilde Girard, Department Leader, Cell Therapy Innovation andDevelopment
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF COMPANIES ANDORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
